29 May 2020

AstraZeneca has entered into a one-year clinical and commercial supply agreement with Oxford BioMedica to manufacture its adenovirus vector-based Covid-19 vaccine candidate, AZD1222, which was developed by the University of Oxford researchers. The agreement will provide AstraZeneca with access to Oxford Biomedica’s 7,800m2 commercial manufacturing centre in Oxford.

PureTech Health has plans to conduct a clinical trial to assess LYT-100 (deupirfenidone) to treat serious respiratory complications that persist even after resolution of Covid-19 infection. Expected to start in the third quarter of this year, the trial will enrol about 150 non-critical patients with respiratory complications.

Novartis has signed a manufacturing deal with US researchers to produce a Covid-19 vaccine candidate, which is based on technology similar to that of the company’s gene therapy drug Zolgensma, according to Reuters. The researchers at Massachusetts General Hospital and Massachusetts Eye and Ear said that manufacturing will occur at Novartis’ gene therapy unit AveXis.

RNA therapeutics company Chimeron Bio has collaborated with George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID) to develop a Covid-19 vaccine candidate. The vaccine will be developed using Chimeron Bio’s ChaESARTM self-amplifying RNA technology, which is designed to deliver immunogenic viral genes to trigger rapid and sustained immune response.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.